Zai Lab Restricted (NASDAQ:ZLAB) Discusses Up to date Monotherapy Section I Information for Zoci and Outlines Subsequent Steps in Medical Growth October 24, 2025 11:00 AM EDT
Firm Members
Rafael Amado – President and Head of International Analysis & Growth
Joshua Smiley – President & COO
Convention Name Members
Jonathan Chang – Leerink Companions LLC, Analysis Division
Li Wang Watsek – Cantor Fitzgerald & Co., Analysis Division
Linhai Zhao – Goldman Sachs Group, Inc., Analysis Division
Yuxi Dong – Jefferies LLC, Analysis Division
Presentation
Operator
Good day, and thanks for standing by. Welcome to the Zai Lab 2025 Triple Assembly Investor Name. [Operator Instructions] Please be aware that at the moment’s convention is being recorded. I’d now like to show the convention over to your speaker, Rafael Amado, President and Head of International Analysis and Growth. Please go forward.
Rafael Amado
President and Head of International Analysis & Growth
Hello, everybody. Thanks a lot for becoming a member of us at the moment. I am Rafael Amado, Zai Lab’s President and Head of International R&D. Earlier than we start, we can be making forward-looking statements at the moment, and I ask you to overview Slide 2 for additional element.
Shifting to Slide 3. This is our agenda. I will start with an summary of our international asset portfolio, adopted by an in depth presentation of the up to date monotherapy Section I dose escalation and dose growth medical knowledge for Zoci that had been introduced earlier at the moment in a plenary session on the ENA Symposium right here in Boston. Then I will share what these outcomes imply for this system and our subsequent steps earlier than opening up the traces on your questions.
Slide 4 highlights the momentum of Zai Lab’s rising international innovation pipeline, which at the moment spans each oncology and immunology, our 2 core focus areas for international growth. Beginning with oncology. On the high left, you may see Zoci, our potential first and best-in-class DLL3 focused